» Articles » PMID: 10931136

Cytokine-mediated Up-regulation of CD55 and CD59 Protects Human Hepatoma Cells from Complement Attack

Overview
Date 2000 Aug 10
PMID 10931136
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatic parenchymal cells respond in many different ways to acute-phase cytokines. Some responses may protect against damage by liver-derived inflammatory mediators. Previous investigations have shown that cytokines cause increased secretion by hepatoma cells of soluble complement regulatory proteins, perhaps providing protection from complement attack. More important to cell protection are the membrane complement regulators. Here we examine, using flow cytometry and Northern blotting, the effects of different cytokines, singly or in combination, on expression of membrane-bound complement regulators by a hepatoma cell line. The combination of tumour necrosis factor-alpha, IL-1beta, and IL-6 caused increased expression of CD55 (three-fold) and CD59 (two-fold) and decreased expression of CD46 at day 3 post-exposure. Interferon-gamma reduced expression of CD59 and strongly antagonized the up-regulatory effects on CD59 mediated by the other cytokines. Complement attack on antibody-sensitized hepatoma cells following a 3-day incubation with the optimum combination of acute-phase cytokines revealed increased resistance to complement-mediated lysis and decreased C3b deposition. During the acute-phase response there is an increased hepatic synthesis of the majority of complement effector proteins. Simultaneous up-regulation of expression of CD55 and CD59 may serve to protect hepatocytes from high local concentrations of complement generated during the acute-phase response.

Citing Articles

DNAJB1-PKAc Kinase Is Expressed in Young Patients with Pediatric Liver Cancers and Enhances Carcinogenic Pathways.

Fleifil Y, Gulati R, Jennings K, Miethke A, Bondoc A, Tiao G Cancers (Basel). 2025; 17(1).

PMID: 39796711 PMC: 11720578. DOI: 10.3390/cancers17010083.


Anti-HER2 Cancer-Specific mAb, HMab-250-hG, Possesses Higher Complement-Dependent Cytotoxicity than Trastuzumab.

Suzuki H, Ohishi T, Tanaka T, Kaneko M, Kato Y Int J Mol Sci. 2024; 25(15).

PMID: 39125956 PMC: 11313270. DOI: 10.3390/ijms25158386.


Decay-Accelerating Factor Differentially Associates With Complement-Mediated Damage in Synovium After Meniscus Tear as Compared to Anterior Cruciate Ligament Injury.

Holers V, Frank R, Zuscik M, Keeter C, Scheinman R, Striebich C Immune Netw. 2024; 24(2):e17.

PMID: 38725672 PMC: 11076301. DOI: 10.4110/in.2024.24.e17.


A Monocytic Barrier to the Humanization of Immunodeficient Mice.

Du E, Muench M Curr Stem Cell Res Ther. 2023; 19(7):959-980.

PMID: 37859310 PMC: 10997744. DOI: 10.2174/011574888X263597231001164351.


Complement and complement regulatory proteins are upregulated in lungs of COVID-19 patients.

Ge X, Yu Z, Guo X, Li L, Ye L, Ye M Pathol Res Pract. 2023; 247:154519.

PMID: 37244049 PMC: 10165854. DOI: 10.1016/j.prp.2023.154519.


References
1.
Bjorge L, Jensen T, Matre R . Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line. Cancer Immunol Immunother. 1996; 42(3):185-92. PMC: 11037746. DOI: 10.1007/s002620050269. View

2.
Mason J, Yarwood H, Sugars K, Morgan B, Davies K, Haskard D . Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition. Blood. 1999; 94(5):1673-82. View

3.
Colten H . Biosynthesis of complement. Adv Immunol. 1976; 22:67-118. DOI: 10.1016/s0065-2776(08)60548-9. View

4.
Morris K, Aden D, Knowles B, Colten H . Complement biosynthesis by the human hepatoma-derived cell line HepG2. J Clin Invest. 1982; 70(4):906-13. PMC: 370299. DOI: 10.1172/jci110687. View

5.
Chomczynski P, Sacchi N . Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987; 162(1):156-9. DOI: 10.1006/abio.1987.9999. View